Filtered By:
Condition: Diabetes Mellitus
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 233 results found since Jan 2013.

Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center registry in Poland
CONCLUSION: Among cardiovascular risk factors and diseases, HF and DM appeared to increase in-hospital COVID-19 mortality, whereas the use of cardiovascular drugs was associated with lower mortality.PMID:33926173 | DOI:10.33963/KP.15990
Source: Kardiologia Polska - April 30, 2021 Category: Cardiology Authors: Micha ł Terlecki Wiktoria Wojciechowska Marek Klocek Agnieszka Olszanecka Katarzyna Stolarz-Skrzypek Tomasz Grodzicki Maciej Ma łecki Barbara Katra Aleksander Garlicki Monika Boci ąga-Jasik Krzysztof S ładek Andrzej Matyja Jerzy Wordliczek Agnieszka S Source Type: research

Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 monoclonal antibodies
Curr Med Chem. 2021 Feb 21. doi: 10.2174/0929867328666210222092628. Online ahead of print.ABSTRACTCardiovascular disease (CVD) remains the primary cause of global morbidity and mortality. CVD includes various life-threatening conditions such as myocardial infarction, stroke and peripheral arterial diseases. In this context, atherosclerosis continues to play the principal role in the pathogenesis of these conditions. Atherosclerosis emanates from a set of modifiable and non-modifiable risk factors that include age, male gender, family history, obesity, smoking, diabetes mellitus and hypertension. Recent evidence classifies ...
Source: Current Medicinal Chemistry - March 3, 2021 Category: Chemistry Authors: Adel Hajj Ali Nour Younis Rola Abdallah Farah Shaer Ali Dakroub Mohammed Ayoub Rabah Iratni Hadi Mohamad Yassine Kazem Zibara Alexander Orekhov Ahmed Fawzy El-Yazbi Ali Eid Source Type: research

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) – Still to be Considered in the Presence of Vascular Risk Factors
We report a 46-year-old male with a 9 and 3-month history of progressive unilateral lower limb weakness and dysarthria, respectively. He had a history of diabetes mellitus but no hypertension, hyperlipidemia, or smoking history. Both parents had a stroke at the age of 65 years. Neurological examination was significant for moderate dysarthria and reduced right upper limb dexterity. Magnetic resonance imaging (MRI) of the brain revealed extensive white matter disease, lacunar infarcts, and a few microhemorrhages. Electron microscopy of his skin biopsy showed electron-dense deposits of extracellular osmiophilic granular mater...
Source: Case Reports in Neurology - December 14, 2020 Category: Neurology Source Type: research

Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarc-tion Patients with Primary Percutaneous Coronary Intervention.
CONCLUSION: The results mentioned above suggested that pitavastatin combined with ezetimibe was an effective approach to STEMI patients with non-IRA disease undergoing primary PCI. The results obtained in this study have provided a novel way for the treatment of STEMI patients with non-IRA disease undergoing primary PCI. PMID: 32598255 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - June 28, 2020 Category: Biotechnology Authors: Zhao B, Li GP, Peng JJ, Ren LH, Lei LC, Ye HM, Wang ZY, Zhao S Tags: Curr Pharm Biotechnol Source Type: research

Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Purpose of review To discuss the current evidence regarding the relationship between omega-3 fatty acid intake and atherosclerotic cardiovascular disease (ASCVD) risk. Recent findings Combined results from randomized controlled trials using low-dosage (≤1.8 g/day of ethyl esters) eicosapentaenoic acid (EPA) or EPA + docosahexaenoic acid (DHA) suggest a small benefit for reducing coronary heart disease risk. The Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) that administered 4 g/day icosapent ethyl (IPE) to individuals on statin at high or very high ASCVD risk with elevated triglyceri...
Source: Current Opinion in Cardiology - June 6, 2020 Category: Cardiology Tags: LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Anthony S. Wierzbicki Source Type: research